Clinical Trials
39 trialsNCT04804709 2025-06-08
Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG)
Columbia University
Phase 1 Terminated
NCT01324635 2025-05-02
Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors
Thomas Jefferson University
Phase 1 Terminated
NCT04897880 2025-02-24
NORTH
Australian & New Zealand Children's Haematology/Oncology Group
Phase 2 Terminated
NCT04956302 2024-06-06
Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 1 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT04341311 2024-02-15
DIPG
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT04326764 2023-02-16
Panobinostat Maintenance After HSCT fo High-risk AML and MDS
Goethe University
Phase 3 Terminated
NCT01582009 2022-08-15
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT03256045 2022-05-09
Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
University of Washington
Phase 2 Terminated
NCT00490776 2021-08-18
Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)
Novartis
Phase 2 Terminated
NCT00449761 2021-07-15
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
Novartis
Phase 2 Terminated
NCT00445068 2021-07-14
Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma
Novartis
Phase 2 Terminated
NCT00493766 2020-12-19
Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone
Novartis
Phase 1 Terminated
NCT00823290 2020-12-14
Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)
University of Erlangen-Nürnberg Medical School
Phase 1 Terminated
NCT00985946 2019-12-09
Study of Panobinostat in Patients With Neuroendocrine Tumors
University of Wisconsin, Madison
Phase 2 Terminated
NCT02518750 2019-04-03
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT02676323 2018-11-14
Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome
St. Jude Children's Research Hospital
Phase 1 Terminated
NCT00939159 2018-08-23
Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02720510 2018-07-24
PANORAMA4
Novartis
Phase 2 Terminated
NCT01056601 2017-12-28
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00925132 2017-07-02
Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
University of Iowa
Phase 1/2 Terminated
NCT00958022 2017-06-22
Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer
University of Pittsburgh
Phase 1 Terminated
NCT01282476 2017-05-09
Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Massachusetts General Hospital
Phase 2 Terminated
NCT01032148 2017-01-12
Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
Roswell Park Cancer Institute
Phase 1 Terminated
NCT00978432 2016-11-25
Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Duke University
Phase 2 Terminated
NCT00567879 2016-05-09
A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab
Novartis
Phase 1/2 Terminated
NCT00777335 2015-11-24
Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer
Translational Research in Oncology
Phase 2 Terminated
NCT00907179 2015-07-22
Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer
University of Pittsburgh
Phase 1 Terminated
NCT01238965 2015-05-27
Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy
University of Southern California
Phase 1 Terminated
NCT00891033 2015-02-23
Panobinostat/Velcade in Multiple Myeloma
University of Arkansas
Phase 1 Terminated
NCT01194908 2015-01-26
Re-expression of ER in Triple Negative Breast Cancers
Emory University
Phase 1/2 Terminated
NCT00723203 2014-09-09
Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
City of Hope Medical Center
Phase 2 Terminated
NCT01090973 2013-12-16
Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00550199 2013-08-19
LBH589 and Gemcitabine in the Treatment of Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Terminated
NCT01528501 2013-05-01
HDAC
Technical University of Munich
Phase 2 Terminated
NCT00699296 2012-11-27
Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma
Novartis
Phase 2 Terminated
NCT00873002 2012-03-20
Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT00848523 2010-07-16
Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors
Neurological Surgery, P.C.
Phase 2 Terminated
NCT00419536 2010-04-08
Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone
Novartis
Phase 1 Terminated